AlloVir, Inc. ALVR
9.81 0.00 (+0.00%)
At closeMar 18, 2025, 4:00 PM EDT
9.55 Day range 10.32
52-week range unavailable
- Market cap
- 54.80M
- Shares out
- 115.57M
- Forward P/E
- -1.48
- Volume
- 9.40K
- Open
- 9.55
- Previous close
- 9.81
- Day's range
- 9.55 – 10.32
- Beta
- 0.74
- Price target
- 1.50 (-84.7%)
No chart data for this range yet.
Key statistics
- Enterprise value
- -58.81M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -58.26M
- Total cash
- 129.61M
- Total debt
- 9.00M
- Return on equity
- -80.33%
- Short % of float
- 6.34%
- 50-day average
- 0.65036
- 200-day average
- 0.736615
Analyst view
Price target (mean) 1.50
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ALVR Revenue — quarterly 0
ALVR Net income — quarterly -18.27M
ALVR EPS — quarterly -3.68
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.14 | -0.04 | +0.10 | +71.43% |
| Aug 9, 2024 | Jun 1, 2024 | -0.10 | -0.05 | +0.05 | +50.00% |
| May 13, 2024 | Mar 1, 2024 | -0.16 | -0.18 | -0.02 | -12.50% |
| Mar 15, 2024 | Dec 1, 2023 | -0.43 | -0.53 | -0.10 | -23.26% |
| Nov 2, 2023 | Sep 1, 2023 | -0.42 | -0.39 | +0.03 | +7.14% |
| Aug 3, 2023 | Jun 1, 2023 | -0.45 | -0.48 | -0.03 | -6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 26, 2023 | B of A Securities | down | Buy | Underperform |
| Dec 22, 2023 | Leerink Partners | down | Outperform | Market Perform |
| Dec 22, 2023 | Piper Sandler | down | Overweight | Neutral |
| Dec 22, 2023 | JP Morgan | down | Overweight | Underweight |
| Aug 18, 2023 | B of A Securities | init | — | Buy |
| Aug 7, 2023 | Morgan Stanley | reit | Overweight | Overweight |
About AlloVir, Inc.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allovir.com
News
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders 
Head to Head Review: AlloVir (NASDAQ:ALVR) versus SQZ Biotechnologies (NYSE:SQZ) 
ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders 
ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm 
Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation 
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Investors to Learn More About the Investigation 
AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation 
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out 
Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect 
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities
Your note
Sign in to keep a note on ALVR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORNSTEIN JEFFREY S | Director | Stock Award(Grant) | Jun 5, 2024 | 110,197 |
| BRAINARD DIANA | Chief Executive Officer | Sale | Nov 18, 2024 | 723,363 |
| BRENNER MALCOLM | Director | Stock Award(Grant) | Jun 5, 2024 | 263,929 |
| HAGEN BRETT R. | Officer | Sale | Nov 18, 2024 | 68,506 |
| HALLAL DAVID L | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 5, 2024 | 19,677,500 |
| JOVAN-EMBIRICOS MORANA | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 5, 2024 | 26,603,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 9.77% | 11,294,585 | 5.36M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 9.69% | 11,202,000 | 5.31M | Sep 29, 2024 |
| Siren, L.L.C. | 5.71% | 6,597,167 | 3.13M | Sep 29, 2024 |
| Millennium Management Llc | 2.84% | 3,284,800 | 1.56M | Sep 29, 2024 |
| Vanguard Group Inc | 2.29% | 2,647,010 | 1.26M | Sep 29, 2024 |
| Redmile Group, LLC | 1.65% | 1,907,969 | 904.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.53% | 1,771,721 | 840.15K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.74% | 858,612 | 407.15K | Sep 29, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.25% | 288,696 | 136.90K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 286,410 | 135.81K | Oct 30, 2024 |
| Variable Insurance Products Fd II-Disciplined Small Cap Portfolio | 0.16% | 179,553 | 85.14K | Sep 29, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.10% | 120,724 | 57.25K | Oct 30, 2024 |